0001213900-22-063921.txt : 20221014 0001213900-22-063921.hdr.sgml : 20221014 20221013185730 ACCESSION NUMBER: 0001213900-22-063921 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20221012 ITEM INFORMATION: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20221014 DATE AS OF CHANGE: 20221013 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Joway Health Industries Group Inc CENTRAL INDEX KEY: 0001263364 STANDARD INDUSTRIAL CLASSIFICATION: BLANK CHECKS [6770] IRS NUMBER: 980221494 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 333-108715 FILM NUMBER: 221309949 BUSINESS ADDRESS: STREET 1: NO 19 BAOWANG ROAD STREET 2: BAODI ECONOMIC DEVELOPMENT ZONE CITY: TIANJIN, PRC STATE: F4 ZIP: 300180 BUSINESS PHONE: 862258896888 MAIL ADDRESS: STREET 1: NO 19 BAOWANG ROAD STREET 2: BAODI ECONOMIC DEVELOPMENT ZONE CITY: TIANJIN, PRC STATE: F4 ZIP: 300180 FORMER COMPANY: FORMER CONFORMED NAME: G2 VENTURES INC DATE OF NAME CHANGE: 20030911 8-K 1 ea167066-8k_joway.htm CURRENT REPORT
0001263364 false --12-31 0001263364 2022-10-12 2022-10-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(D) OF

THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): October 12, 2022

 

Joway Health Industries Group Inc.

(Exact Name of Registrant as Specified in its Charter)

 

Nevada   333-108715   98-0221494

(State or Other Jurisdiction

of Incorporation)

 

(Commission File No.)

 

(I.R.S. Employer

Identification No.)

 

600 South 3rd Street

Las Vegas, Nevada

 

89101

(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s telephone number, including area code:

702-384-1990

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol   Name of exchange on which registered
N/A   N/A   N/A

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

 

On October 12, 2022, the Company’s Board of Directors and the majority of stockholders of the Company approved and adopted Amended and Restated Articles of Incorporation (the “Articles of Incorporation”) and, on the same day, the Board of Directors adopted and approved Amended and Restated Bylaws (the “Bylaws”). The Certificate for the Articles of Incorporation was filed with the Secretary of State on October 13, 2022. The Company’s Articles of Incorporation were amended to increase the Company’s authorized common stock from two-hundred million shares (200,000,000) to five-hundred million shares (500,000,000) and preferred stock from one million shares (1,000,000) to ten million shares (10,000,000). The Company also amended the Articles of Incorporation to opt out of the provisions of §78.378 through §78.379 and §78.411 through §78.444 of the Nevada Revised Statues, generally known as the “Control Share Acquisition Statute” and “Combinations with Interested Stockholders”, respectively.

 

This summary description of the material terms of the Articles of Incorporation and Bylaws does not purport to be complete and is qualified in its entirety by reference to the full text of these documents, copies of each are attached hereto as Exhibit 3.1 and Exhibit 3.2 and are incorporated herein by reference. 

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No.   Description
3.1   Amended and Restated Articles of Incorporation of Joway Health Industries Group Inc.
3.2   Amended and Restated Bylaws of Joway Health Industries Group Inc.
104   Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document).

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Joway Health Industries Group Inc.
     
Date: October 12, 2022 By: /s/ Ramon Lata
    Ramon Lata
    President

 

 

2

 

 

EX-3.1 2 ea167066ex3-1_joway.htm AMENDED AND RESTATED ARTICLES OF INCORPORATION OF JOWAY HEALTH INDUSTRIES GROUP INC

Exhibit 3.1

 

AMENDED AND RESTATED ARTICLES OF INCORPORATION OF

JOWAY HEALTH INDUSTRIES GROUP INC.

 

FIRST: The name of the corporation is Joway Health Industries Group Inc. (the “Corporation”).

 

SECOND: The nature of the business or purposes of the Corporation is to engage in any lawful act or activity for which corporations may be organized under Chapter 78 of Nevada Revised Statutes (the “NRS”).

 

THIRD:

 

1. The total number of shares of stock which the Corporation shall have the authority to issue is 500,000,000 shares of common stock having a par value of $0.001 per share, which shares shall not be subject to any preemptive rights, and 10,000,000 shares of preferred stock having a par value of $0.001 per share.

 

2. Pursuant to NRS §78.195 and §78.196, a statement of the voting powers, designations, preferences, limitations, restrictions and relative rights thereof, in respect of each class of capital stock is as follows:

 

A.PREFERRED STOCK

 

(i) The board of directors is hereby expressly authorized at any time, and from time to time, to provide by resolution for the issuance of shares of preferred stock in one or more series, with such voting powers, full or limited, or no voting powers, and with such designations, preferences and relative, participating, optional or other rights, and qualifications or restrictions thereof, as shall be stated and expressed in the resolution or resolutions providing for the issue thereof adopted by a majority of the board of directors then in office a including (without limiting the generality thereof) the following as to each such series: (a) the designation of such series; (b) the dividends, if any, payable with respect to such series, the rates or basis for determining such dividends, and any conditions and dates upon which such dividends shall be payable, the preferences, if any, of such dividends over, or the relation of such dividends to, the dividends payable on the Common Stock or any other series of preferred stock, whether such dividends shall be noncumulative or cumulative, and, if cumulative, the date or dates from which such dividends shall be cumulative; (c) whether shares of such series shall be redeemable at the option of the board of directors or the holder, or both, upon the happening of a specified event and, if redeemable, whether for cash, property or rights, including securities of the Corporation, the time, prices or rates and any adjustment and other terms and conditions of such redemption; (d) the terms and amount of any sinking, retirement or purchase fund provided for the purchase or redemption of shares of such series; (e) whether shares of such series shall be convertible into or exchangeable for shares of Common Stock or any other series of preferred stock, at the option of the Corporation or of the holder, or both, or upon the happening of a specified event and, if provision be made for such conversion or exchange, the terms, prices, rates, adjustments and any other terms and conditions thereof; (f) the extent, if any, to which the holders of shares of such series shall be entitled to vote with respect to the election of directors or otherwise, including, without limitation, the extent, if any, to which such holders shall be entitled, voting as a series or as a part of a class, to elect one or more directors upon the happening of a specified event or otherwise; (g) the restrictions, if any, on the issue or reissue of shares of such series or any other series; (h) the extent, if any, to which the holders of shares of such series shall be entitled to preemptive rights; and (i) the rights of the holders of shares of such series upon the liquidation of the Corporation or any distribution of its assets.

 

 

 

 

(ii) Unless the board of directors provides to the contrary in the resolution which fixes the characteristics of a series of preferred stock, neither the consent by series, or otherwise, of the holders of any outstanding preferred stock nor the consent of the holders of any outstanding common stock shall be required for the issuance of any new series of preferred stock regardless of whether the rights and preferences of the new series of preferred stock are senior or superior, in any way, to the outstanding series of preferred stock or the common stock.

 

(iii) Before the Corporation shall issue any shares of preferred stock of any series, a certificate of designation setting forth a copy of the resolution or resolutions of the board of directors, and establishing the voting powers, designations, preferences, the relative, participating, optional, or other rights, if any, and the qualifications, limitations, and restrictions, if any, relating to the shares of preferred stock of such series, and the number of shares of preferred stock of such series authorized by the board of directors to be issued shall be made and signed by an officer of the corporation and filed in the manner prescribed by the NRS.

 

B.COMMON STOCK

 

(i) Dividends and Distributions. No payment of dividends or distributions shall be made to the holders of shares of common stock unless and until the holders of preferred stock receive any preferential amounts to which they are entitled under this ARTICLE THIRD or in the resolution or resolutions providing for the issue of shares of preferred stock. Subject to the limitation set forth in the preceding sentence and except as provided by these Articles of Incorporation or in the resolution or resolutions providing for the issue of shares of preferred stock, the holders of shares of common stock shall be entitled to receive such dividends and distributions as may be declared upon such shares of common stock, from time to time by a resolutions or resolutions adopted by the board of directors.

 

(ii) Voting Rights. All holders of common stock shall be entitled to notice of any stockholders’ meeting. Subject to the provisions of any applicable law and except as otherwise provided in these Articles of Incorporation or by the resolution or resolutions providing for the issue of shares of preferred stock, all voting rights shall be vested solely in the common stock. The holders of shares of common stock shall be entitled to vote upon the election of directors and upon any other matter submitted to the stockholders for a vote. Each share of common stock issued and outstanding shall be entitled to one noncumulative vote. A fraction of a share of common stock shall not be entitled to any voting rights whatsoever.

 

(iii) Liquidation, Dissolution or Winding Up. Except as otherwise provided in these Articles of Incorporation and subject to the rights of holders, if any, of preferred stock to receive preferential liquidation distributions to which they are entitled under this ARTICLE THIRD or under the resolution or resolutions providing for the issue of shares of preferred stock, in the event of any liquidation, dissolution or winding up of the Corporation, whether voluntary or involuntary, after payment or provision for payment of the debts and liabilities of the Corporation, all assets of the Corporation shall be shared pro rata among the holders of the common stock.

 

2

 

 

3. Except as otherwise providing in these Articles of Incorporation or by applicable law, the Corporation’s capital stock, regardless of class, may be issued for such consideration and for such corporate purposes as the board of directors may from time to time determine by a resolution or resolutions adopted by a majority of the board of directors then in office.

 

4. As specifically permitted pursuant to § 78.288 of the NRS, the Corporation may make a distribution (including dividends on, or redemptions or repurchases of shares of its capital stock) even if, after giving effect to such distributions, the total assets of the Corporation would be less than the sum of its total liabilities plus the amount that would be needed at the time of a dissolution to satisfy the preferential rights of any preferred shareholders.

 

FOURTH: The Corporation shall have perpetual existence.

 

FIFTH:

 

1. The management of the business and the conduct of the affairs of the Corporation shall be vested in its board of directors.

 

2. The board of directors shall consist of not less than one (1) nor more than fifteen (15) persons, the exact numbers to be fixed from time to time by the board of directors pursuant to a resolution adopted by a majority of directors then in office; provided, however, that such maximum number may be increased from time to time to reflect the rights of holders of preferred stock to elect directors in accordance with the terms of these Articles of Incorporation or of the resolution or resolutions adopted by a majority of the board of directors then in office providing for the issue of shares of preferred stock.

 

3. One or more directors or the entire board of directors may be removed at any time for cause by the affirmative of the holders of two-thirds of the outstanding shares of capital stock of the Corporation entitled to vote generally in the election of directors (considered for this purpose as one class), cause for purposes of these Articles of Incorporation shall be: (i) any fraudulent or dishonest act or activity by the director; or (ii) behavior materially detrimental to the business of the corporation.

 

4. Whenever the Corporation shall be authorized to issue only one class of stock, each outstanding share shall entitle the holder thereof to notice of, and the right to vote at, any meeting of stockholders. Whenever the Corporation shall be authorized to issue more than one class of stock, no outstanding share of any class of stock which is denied voting power under the provisions of these Articles of Incorporation shall entitle the holder thereof to the right to vote at any meeting of stockholders except as otherwise provided by applicable law; provided, that no share of any such class which is otherwise denied voting power shall entitle the holder thereof to vote upon the increase or decrease in the number of authorized shares of said class.

 

3

 

 

SIXTH: The liability of directors and officers of the Corporation shall be eliminated or limited to the fullest extent permitted by the NRS. If the NRS is amended to further eliminate or limit or authorize corporate action to further eliminate or limit the liability of directors or officers, the liability of directors and officers of the Corporation shall be eliminated or limited to the fullest extent permitted by the NRS, as so amended from time to time.

 

SEVENTH:

 

1. The Corporation shall to the fullest extent permitted by the NRS as the same may be amended and supplemented (but in the case of any such amendment or supplement, only to the extent that such amendment or supplement permits the Corporation to provide broader indemnification rights than said law permitted the Corporation to provide prior to such amendment or supplement), indemnify any and all directors and officers whom it shall have power to indemnify under the NRS from and against any and all of the expenses, liabilities, or other matters referred to in or covered by the NRS, and the indemnification provided for herein shall continue as to a person who has ceased to be a director or officer and shall inure to the benefit of the heirs, executors and administrators of such person. The Corporation may, in its sole discretion and to the fullest extent permitted by the NRS as the same may be amended or supplemented, indemnify any and all employees and agents whom it shall have the power to indemnify under the NRS from and against any and all of the expenses, liabilities, or other matters referred to in or covered by the NRS, and the indemnification provided for herein shall continue as to a person who has ceased to be an employee or agent and shall inure to the benefit of the heirs, executors, and administrators of such person.

 

2. The Corporation shall pay the expenses incurred in defending any proceeding against a director or officer which is or may be subject to indemnification pursuant to this SEVENTH in advance of final disposition of such proceeding; provided, however, that the payment of such expenses incurred by a director or officer shall be made only upon receipt of an undertaking by the director or officer to repay all amounts advanced it if should be ultimately determined that the director or officer is not entitled to be indemnified under this ARTICLE SEVENTH or otherwise. The Corporation may, in its sole discretion, advance expenses incurred by its employees or agents to the same extent as expenses may be advanced to its directors and officers hereunder.

 

3. The rights conferred on any person by this ARTICLE SEVENTH shall be deemed contract rights and shall not be exclusive of any other rights which such person may have or hereafter acquire under any statute, provision of these Articles of Incorporation or the Corporation’s Bylaws, agreement, or vote of stockholders or disinterested directors or otherwise.

 

4. The Corporation may purchase and maintain insurance to protect itself and any other director, officer, employee or agent of the Corporation or any corporation, partnership, joint venture, trust or other enterprise against any liability, whether or not the Corporation would have the power to indemnify such person under the NRS.

 

4

 

 

EIGHTH: Any repeal or modification of ARTICLE SIXTH OR SEVENTH approved by the stockholders of the Corporation shall be prospective only, and shall not adversely affect any limitation on the liability of a director or officer of the Corporation existing as of the time of such repeal or modification. In the event of any conflict between Sections 3 or 4 above and any other Article of the Articles, the terms and provisions of Sections 3 or 4 above shall control. From time to time any of the provisions of these Articles of Incorporation may be amended, altered or repealed in accordance with the laws of the State of Nevada at the time in force; provided, however, that the affirmative vote of the holders of at least 66- 2/3% of the outstanding shares of the Corporation’s capital stock entitled to vote thereon and 66- 2/3% of the members of the Board of Directors then holding office is required to amend those provisions of these Articles of Incorporation set forth in ARTICLES SIXTH, SEVENTH OR EIGHTH.

 

NINTH:

 

1. Control Share Acquisition Exemption. The Corporation elects not to be governed by the provisions of NRS §78.378 through NRS §78.3793, inclusive, generally known as the “Control Share Acquisition Statute.”

 

2. Combinations With Interested Stockholders. The Corporation elects not to be governed by the provisions of NRS §78.411 through NRS §78.444, inclusive.

 

TENTH: The board of directors is expressly granted the exclusive power to make, amend, alter, or repeal the bylaws of the Corporation pursuant to NRS 78.120.

 

5

 

 

IN WITNESS WHEREOF, the undersigned has executed these Amended and Restated Articles of Incorporation as of 12th day of October 2022.

 

  /s/ Ramon Lata
  Name: Ramon Lata
  Title: President

 

 

6

 

 

EX-3.2 3 ea167066ex3-2_joway.htm AMENDED AND RESTATED BYLAWS OF JOWAY HEALTH INDUSTRIES GROUP INC

Exhibit 3.2

 

AMENDED AND RESTATED

 

BYLAWS OF

 

Joway Health Industries Group Inc.

 

Article I. Principal Executive Offices

 

The principal executive office of Joway Health Industries Group Inc. (the “Corporation”) shall be at 600 South 3rd Street, Las Vegas, Nevada, or such other place or places within or without the State of Nevada as the board of directors shall from time to time determine.

 

Article II. Meeting of Stockholders

 

Section 2.01 Place of Meetings. All annual and special meetings of stockholders shall be held at the principal executive office of the Corporation or at such other place within or without the State of Nevada as the board of directors may determine and as designated in the notice of such meeting.

 

Section 2.02 Annual Meeting. A meeting of the stockholders of the Corporation for the election of directors and for the transaction of any other business of the Corporation shall be held annually at such date and time as the board of directors may determine.

 

Section 2.03 Special Meetings. Special meeting of the stockholders of the Corporation for any purpose or purposes may be called at any time by the board of directors of the Corporation, or by a committee of the board of directors which has been duly designated by the board of directors and whose powers and authorities, as provided in a resolution of the board of directors or in the Bylaws of the Corporation, include the power and authority to call such meetings but such special meetings may not be called by another person or persons.

 

Section 2.04 Conduct of Meetings. Annual and special meetings shall be conducted in accordance with these Bylaws or as otherwise prescribed by the board of directors. The chairman or the chief executive officer of the Corporation shall preside at such meetings.

 

Section 2.05 Notice of Meeting. Written notice stating the place, day and hour of the meeting and the purpose or purposes for which the meeting is called shall be mailed by the secretary or the officer performing his duties, not less than ten days nor more than sixty days before the meeting to each stockholder of record entitled to vote at such meeting. If mailed, such notice shall be deemed to be delivered when deposited in the United States mail, addressed to the stockholder at his address as it appears on the stock transfer books or records of the Corporation as of the record date prescribed in Section 6, with postage thereon prepaid. If a stockholder be present at a meeting, or in writing waive notice thereof before or after the meeting, notice of the meeting to such stockholder shall be unnecessary. When any stockholders’ meeting, either annual or special, is adjourned for thirty days or more, notice of the adjourned meeting shall be given as in the case of an original meeting. It shall not be necessary to give any notice of the time and place of any meeting adjourned for less than thirty days or of the business to be transacted at such adjourned meeting, other than an announcement at the meeting at which such adjournment is taken.

 

 

 

 

Section 2.06 Fixing of Record Date. For the purpose of determining stockholders entitled to notice of or to vote at any meeting of stockholders, or any adjournment thereof, or stockholders entitled to receive payment of any dividend, or in order to make a determination of stockholders for any other proper purpose, the board of directors shall fix in advance a date as the record date for any such determination of stockholders. Such date in any case shall be not more than sixty days, and in case of a meeting of stockholders, not less than ten days prior to the date on which the particular action, requiring such determination of stockholders, is to be taken.

 

When a determination of stockholders entitled to vote at any meeting of stockholders has been made as provided in this section, such determination shall apply to any adjournment thereof.

 

Section 2.07 Voting Lists. The officer or agent having charge of the stock transfer books for shares of the Corporation shall make, at least ten days before each meeting of stockholders, a complete record of the stockholders entitled to vote at such meeting or any adjournment thereof, with the address of and the number of shares held by each. The record, for a period of ten days before such meeting, shall be kept on file at the principal executive office of the Corporation, whether within or outside the State of Nevada, and shall be subject to inspection by any stockholder for any purpose germane to the meeting at any time during usual business hours. Such record shall also be produced and kept open at the time and place of the meeting and shall be subject to the inspection of any stockholder for any purpose germane to the meeting during the whole time of the meeting. The original stock transfer books shall be prima facie evidence as to who are the stockholders entitled to examine such record or transfer books or to vote at any meeting of stockholders.

 

Section 2.08 Quorum. Thirty-three and 33/100 (33 1/3%) percent of the outstanding shares of the Corporation entitled to vote, represented in person or by proxy, shall constitute a quorum at a meeting of stockholders. If less than thirty-three and 33/100 (33 1/3%) percent of the outstanding shares are represented at a meeting, a majority of the shares so represented may adjourn the meeting from time to time without further notice. As such adjourned meeting at which a quorum shall be present or represented, any business may be transacted which might have been transacted at the meeting as originally noticed. The stockholders present at a duly organized meeting may continue to transact business until adjournment, notwithstanding the withdrawal of enough stockholder to leave less than a quorum.

 

Section 2.09 Proxies. At all meetings of stockholders, a stockholder may vote by proxy executed in writing by the stockholder or by his duly authorized attorney in fact. Proxies solicited on behalf of the management shall be voted as directed by the stockholder or, in the absence of such direction, as determined by a majority of the board of directors. No proxy shall be valid after eleven months from the date of its execution unless otherwise provided in the proxy.

 

Section 2.10 Voting. At each election for directors every stockholder entitled to vote at such election shall be entitled to one vote for each share of stock held. Unless otherwise provided by the Articles of Incorporation, by statute, or by these Bylaws, a majority of those votes cast by stockholders at a lawful meeting shall be sufficient to pass on a transaction or matter, except in the election of directors, which election shall be determined by a plurality of the votes of the shares present in person or by proxy at the meeting and entitled to vote on the election of directors.

 

2

 

 

Section 2.11 Voting of Shares in the Name of Two or More Persons. When ownership of stock stands in the name of two or more persons, in the absence of written directions to the Corporation to the contrary, at any meeting of the stockholders of the Corporation any one or more of such stockholders may cast, in person or by proxy, all votes to which such ownership is entitled. In the event an attempt is made to cast conflicting votes, in person or by proxy, by the several persons in whose name shares of stock stand, the vote or votes to which these persons are entitled shall be cast as directed by a majority of those holding such stock and present in person or by proxy at such meeting, but no votes shall be cast for such stock if a majority cannot agree.

 

Section 2.12 Voting of Shares by Certain Holders. Shares standing in the name of another corporation may be voted by any officer, agent or proxy as the Bylaws of such corporation may prescribe, or, in the absence of such provision, as the board of directors of such corporation may determine. Shares held by an administrator, executor, guardian or conservator may be voted by him, either in person or by proxy, without a transfer of such shares into his name. Shares standing in the name of a trustee may be voted by him, either in person or by proxy, but no trustee shall be entitled to vote shares held by him without a transfer of such shares into his name. Shares standing in the name of a receiver may be voted by such receiver, and shares held by or under the control of a receiver may be voted by such receiver without the transfer thereof into his name if authority to do so is contained in an appropriate order of the court or other public authority by which such receiver was appointed.

 

A stockholder whose shares are pledged shall be entitled to vote such shares until the shares have been transferred into the name of the pledgee and thereafter the pledgee shall be entitled to vote the shares so transferred.

 

Neither treasury shares of its own stock held by the Corporation, nor shares held by another corporation, if a majority of the shares entitled to vote for the election of directors of such other corporation are held by the Corporation, shall be voted at any meeting or counted in determining the total number of outstanding shares at any given time for purposes of any meeting.

 

Section 2.13 Inspectors of Election. In advance of any meeting of stockholders, the chairman of the board or the board of directors may appoint any persons, other than nominees for office, as inspectors of election to act at such meeting or any adjournment thereof. The number of inspectors shall be either one or three. If the board of directors so appoints either one or three inspectors, that appointment shall not be altered at the meeting. If inspectors of election are not so appointed, the chairman of the board may make such appointment at the meeting. In case any person appointed as inspector fails to appear or fails or refuses to act, the vacancy may be filled by appointment in advance of the meeting or at the meeting by the chairman of the board or the president.

 

Unless otherwise prescribed by applicable law, the duties of such inspectors shall include: determining the number of shares of stock and the voting power of each share, the shares of stock represented at the meeting, the existence of a quorum, the authenticity, validity and effect of proxies; receiving votes, ballots or consents; hearing and determining all challenges and questions in any way arising in connection with the right to vote; counting and tabulating all votes or consents; determining the result; and such acts as may be proper to conduct the election or vote with fairness to all stockholders.

 

3

 

 

Section 2.14 Nominating Committee. The board of directors or a committee appointed by the board of directors shall act as nominating committee for selecting the management nominees for election as directors. Except in the case of a nominee substituted as a result of the death or other incapacity of a management nominee, the nominating committee shall deliver written nominations to the secretary at least twenty days prior to the date of the annual meeting. Provided such committee makes such nominations, no nominations for directors except those made by the nominating committee shall be voted upon at the annual meeting unless other nominations by stockholders are made in writing and delivered to the secretary of the Corporation in accordance with the provisions of the Corporation’s Articles of Incorporation.

 

Section 2.15 New Business. Any new business to be taken up at the annual meeting shall be stated in writing and filed with the secretary of the Corporation in accordance with the provisions of the Corporation’s Articles of Incorporation. This provision shall not prevent the consideration and approval or disapproval at the annual meeting of reports of officers, directors and committees, but in connection with such reports no new business shall be acted upon at such annual meeting unless stated and filed as provided in the Corporation’s Articles of Incorporation.

 

Article III. Board of Directors

 

Section 3.01 General Powers. The business and affairs of the Corporation shall be under the direction of its board of directors. The chairman shall preside at all meetings of the board of directors.

 

Section 3.02 Number, Term and Election. The number of directors of the Corporation shall be such number, not less than one nor more than 15 (exclusive of directors, if any, to be elected by holders of preferred stock of the Corporation), as shall be provided from time to time in a resolution adopted by the board of directors, provided that no decrease in the number of directors shall have the effect of shortening the term of any incumbent director, and provided further that no action shall be taken to decrease or increase the number of directors from time to time unless at least two-thirds of the directors then in office shall concur in said action. Exclusive of directors, if any, elected by holders of preferred stock, vacancies in the board of directors of the Corporation, however caused, and newly created directorships shall be filled by a vote of two-thirds of the directors then in office, whether or not a quorum, and any director so chosen shall hold office for a term expiring at the annual meeting of stockholders at which the term of the class to which the director has been chosen expires and when the director’s successor is elected and qualified.

 

Section 3.03 Regular Meetings. A regular meeting of the board of directors shall be held at such time and place as shall be determined by resolution of the board of directors without other notice than such resolution.

 

Section 3.04 Special Meetings. Special meetings of the board of directors may be called by or at the request of the chairman, the chief executive officer or one-third of the directors. The person calling the special meetings of the board of directors may fix any place as the place for holding any special meeting of the board of directors called by such persons.

 

Members of the board of the directors may participate in special meetings by means of telephone conference or similar communications equipment by which all persons participating in the meeting can hear each other. Such participation shall constitute presence in person.

 

4

 

 

Section 3.05 Notice. Written notice of any special meeting shall be given to each director at least two days previous thereto delivered personally or by telegram or at least seven days previous thereto delivered by mail at the address at which the director is most likely to be reached. Such notice shall be deemed to be delivered when deposited in the United States mail so addressed, with postage thereon prepaid if mailed or when delivered to the telegraph company if sent by telegram. Any director may waive notice of any meeting by a writing filed with the secretary. The attendance of a director at a meeting shall constitute a waiver of notice of such meeting, except where a director attends a meeting for the express purpose of objecting to the transaction of any business because the meeting is not lawfully called or convened. Neither the business to be transacted at, nor the purpose of, any meeting of the board of directors need be specified in the notice or waiver of notice of such meeting.

 

Section 3.06 Quorum. A majority of the number of directors fixed by Section 2 shall constitute a quorum for the transaction of business at any meeting of the board of directors, but if less than such majority is present at a meeting, a majority of the directors present may adjourn the meeting from time to time. Notice of any adjourned meeting shall be given in the same manner as prescribed by Section 5 of this Article III.

 

Section 3.07 Manner of Acting. The act of the majority of the directors present at a meeting at which a quorum is present shall be the act of the board of directors, unless a greater number is prescribed by these Bylaws, the Articles of incorporation, or the Nevada Revised Statutes.

 

Section 3.08 Action Without a Meeting. Any action required or permitted to be taken by the board of directors at a meeting may be taken without a meeting if a consent in writing, setting forth the action so taken, shall be signed by all of the directors.

 

Section 3.09 Resignation. Any director may resign at any time by sending a written notice of such resignation to the home office of the Corporation addressed to the chairman. Unless otherwise specified therein such resignation shall take effect upon receipt thereof by the chairman.

 

Section 3.10 Vacancies. Any vacancy occurring on the board of directors shall be filled in accordance with the provisions of the Corporation’s Articles of Incorporation. Any directorship to be filled by reason of an increase in the number of directors may be filled by the affirmative vote of two-thirds of the directors then in office or by election at an annual meeting or at a special meeting of the stockholders held for that purpose. The term of such director shall be in accordance with the provisions of the Corporation’s Articles of Incorporation.

 

Section 3.11 Removal of Directors. Any director or the entire board of directors may be removed only in accordance with the provisions of the Corporation’s Articles of Incorporation.

 

Section 3.12 Compensation. Directors, as such, may receive compensation for service on the board of directors. Members of either standing or special committees may be allowed such compensation as the board of directors may determine.

 

5

 

 

Article IV. Committees of the Board of Directors

 

The board of directors may, by resolution passed by a majority of the whole board, designate one or more committees, as they may determine to be necessary or appropriate for the conduct of the business of the Corporation, and may prescribe the duties, constitution and procedures thereof. Each committee shall consist of one or more directors of the Corporation appointed by the chairman. The chairman may designate one or more directors as alternate members of any committee, who may replace any absent or disqualified member at any meeting of the committee.

 

The chairman shall have power at any time to change the members of, to fill vacancies in, and to discharge any committee of the board. Any member of any such committee may resign at any time by giving notice to the Corporation; provided, however, that notice to the board, the chairman of the board, the chief executive officer, the chairman of such committee, or the secretary shall be deemed to constitute notice to the Corporation. Such resignation shall take effect upon receipt of such notice or at any later time specified therein; and, unless otherwise specified therein, acceptance of such resignation shall not be necessary to make it effective. Any member of any such committee may be removed at any time, either with or without cause, by the affirmative vote of a majority of the authorized number of directors at any meeting of the board called for that purpose.

 

Article V. Officers

 

Section 5.01 Positions. The officers of the Corporation shall be a chairman, a president, one or more vice presidents, a secretary and a treasurer, each of whom shall be elected by the board of directors. The board of directors may designate one or more vice presidents as executive vice president or senior vice president. The board of directors may also elect or authorize the appointment of such other officers as the business of the Corporation may require. The officers shall have such authority and perform such duties as the board of directors may from time to time authorize or determine. In the absence of action by the board of directors, the officers shall have such powers and duties as generally pertain to their respective offices.

 

Section 5.02 Election and Term of Office. The officers of the Corporation shall be elected annually by the board of directors at the first meeting of the board of directors held after each annual meeting of the stockholders. If the election of officers is not held at such meeting, such election shall be held as soon thereafter as possible. Each officer shall hold office until his successor shall have been duly elected and qualified or until his death or until he shall resign or shall have been removed in the manner hereinafter provided. Election or appointment of an officer, employee or agent shall not of itself create contract rights. The board of directors may authorize the Corporation to enter into an employment contract with any officer in accordance with state law; but no such contract shall impair the right of the board of directors to remove any officer at any time in accordance with Section 3 of this Article V.

 

Section 5.03 Removal. Any officer may be removed by vote of two-thirds of the board of directors whenever, in its judgment, the best interests of the Corporation will be served thereby, but such removal, other than for cause, shall be without prejudice to the contract rights, if any, of the person so removed.

 

6

 

 

Section 5.04 Vacancies. A vacancy in any office because of death, resignation, removal, disqualification or otherwise, may be filled by the board of directors for the unexpired portion of the term.

 

Section 5.05 Remuneration. The remuneration of the officers shall be fixed from time to time by the board of directors, and no officer shall be prevented from receiving such salary by reason of the fact that he is also a director of the Corporation.

 

Article VI. Contracts, Loans, Checks and Deposits

 

Section 6.01 Contracts. To the extent permitted by applicable law, and except as otherwise prescribed by the Corporation’s Articles of Incorporation or these Bylaws with respect to certificates for shares, the board of directors or the executive committee may authorize any officer, employee, or agent of the Corporation to enter into any contract or execute and deliver any instrument in the name of and on behalf of the Corporation. Such authority may be general or confined to specific instances.

 

Section 6.02 Loans. No loans shall be contracted on behalf of the Corporation and no evidence of indebtedness shall be issued in its name unless authorized by the board of directors. Such authority may be general or confined to specific instances.

 

Section 6.03 Checks, Drafts, Etc. All checks, drafts or other orders for the payment of money, notes or other evidences of indebtedness issued in the name of the Corporation shall be signed by one or more officers, employees or agents of the Corporation in such manner, including in facsimile form, as shall from time to time be determined by resolution of the board of directors.

 

Section 6.04 Deposits. All funds of the Corporation not otherwise employed shall be deposited from time to time to the credit of the Corporation in any of its duly authorized depositories as the board of directors may select.

 

Article VII. Certificates for Shares and Their Transfer

 

Section 7.01 Certificates for Shares. The shares of the Corporation shall be represented by certificates signed by the chairman of the board of directors or the president or a vice president and by the treasurer or an assistant treasurer or the secretary or an assistant secretary of the Corporation and may be sealed with the seal of the Corporation or a facsimile thereof. Any or all of the signatures upon a certificate may be facsimiles if the certificate is countersigned by a transfer agent, or registered by a registrar, other than the Corporation itself or an employee of the Corporation. If any officer who has signed or whose facsimile signature has been placed upon such certificate shall have ceased to be such officer before the certificate is issued, it may be issued by the Corporation with the same effect as if he were such officer at the date of its issue.

 

Section 7.02 Form of Share Certificates. All certificates representing shares issued by the Corporation shall set forth upon the face or back that the Corporation will furnish to any stockholder upon request and without charge a full statement of the designations, preferences, limitations, and relative rights of the shares of each class authorized to be issued, the variations in the relative rights and preferences between the shares of each such series so far as the same have been fixed and determined, and the authority of the board of directors to fix and determine the relative rights and preferences of subsequent series.

 

7

 

 

Each certificate representing shares shall state upon the face thereof that the Corporation is organized under the laws of the State of Nevada; the name of the person to whom issued; the number and class of shares, the designation of the series, if any, which such certificate represents; the par value of each share represented by such certificate, or a statement that the shares are without par value. Other matters in regard to the form of the certificates shall be determined by the board of directors.

 

Section 7.03 Payment for Shares. No certificate shall be issued for any share until such share is fully paid.

 

Section 7.04 Form of Payment for Shares. The consideration for the issuance of shares shall be paid in accordance with the provisions of the Corporation’s Articles of Incorporation.

 

Section 7.05 Transfer of Shares. Transfer of shares of capital stock of the Corporation shall be made only on its stock transfer books. Authority for such transfer shall be given only to the holder of record thereof or by his legal representative, who shall furnish proper evidence of such authority, or by his attorney thereunto authorized by power of attorney duly executed and filed with the Corporation. Such transfer shall be made only on surrender for cancellation of the certificate for such shares. The person in whose name shares of capital stock stand on the books of the Corporation shall be deemed by the Corporation to be the owner thereof for all purposes.

 

Section 7.06 Lost Certificates. The board of directors may direct a new certificate to be issued in place of any certificate theretofore issued by the Corporation alleged to have been lost, stolen, or destroyed, upon the making of an affidavit of that fact by the person claiming the certificate of stock to be lost, stolen, or destroyed. When authorizing such issue of a new certificate, the board of directors may, in its discretion and as a condition precedent to the issuance thereof, require the owner of such lost, stolen, or destroyed certificate, or his legal representative, to give the Corporation a bond in such sum as it may direct as indemnity against any claim that may be made against the Corporation with respect to the certificate alleged to have been lost, stolen, or destroyed.

 

Section 7.07 Book-entry of Shares. The Corporation through its Transfer Agent is authorized to issue shares of its common or preferred stock through Book-entry on the records of the Transfer Agent.

 

Article VIII. Fiscal Year; Annual Audit

 

The fiscal year of the Corporation shall end on the last day of December of each year. The Corporation shall be subject to an annual audit as of the end of its fiscal year by independent public accountants appointed by and responsible to the board of directors.

 

Article IX. Dividends

 

Dividends upon the stock of the Corporation, subject to the provisions of the Articles of Incorporation, if any, may be declared by the board of directors at any regular or special meeting, pursuant to law. Dividends may be paid in cash, in property or in the Corporation’s own stock.

 

Article X. Corporation Seal

 

The corporate seal of the Corporation shall be in such form as the board of directors shall prescribe.

 

Article XI. Amendments

 

The board of directors shall have the exclusive power to amend or repeal these Bylaws, or to adopt new Bylaws.

 

 

8

 

 

EX-101.SCH 4 gtvi-20221012.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 gtvi-20221012_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 gtvi-20221012_pre.xml XBRL PRESENTATION FILE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Cover
Oct. 12, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Oct. 12, 2022
Current Fiscal Year End Date --12-31
Entity File Number 333-108715
Entity Registrant Name Joway Health Industries Group Inc.
Entity Central Index Key 0001263364
Entity Tax Identification Number 98-0221494
Entity Incorporation, State or Country Code NV
Entity Address, Address Line One 600 South 3rd Street
Entity Address, City or Town Las Vegas
Entity Address, State or Province NV
Entity Address, Postal Zip Code 89101
City Area Code 702
Local Phone Number 384-1990
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
XML 8 ea167066-8k_joway_htm.xml IDEA: XBRL DOCUMENT 0001263364 2022-10-12 2022-10-12 iso4217:USD shares iso4217:USD shares 0001263364 false --12-31 8-K 2022-10-12 Joway Health Industries Group Inc. NV 333-108715 98-0221494 600 South 3rd Street Las Vegas NV 89101 702 384-1990 false false false false false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 1 20 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://jowayhealth.com/role/Cover Cover Cover 1 false false All Reports Book All Reports ea167066-8k_joway.htm ea167066ex3-1_joway.htm ea167066ex3-2_joway.htm gtvi-20221012.xsd gtvi-20221012_lab.xml gtvi-20221012_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "ea167066-8k_joway.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "ea167066-8k_joway.htm" ] }, "labelLink": { "local": [ "gtvi-20221012_lab.xml" ] }, "presentationLink": { "local": [ "gtvi-20221012_pre.xml" ] }, "schema": { "local": [ "gtvi-20221012.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 20, "memberCustom": 0, "memberStandard": 0, "nsprefix": "GTVI", "nsuri": "http://jowayhealth.com/20221012", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "ea167066-8k_joway.htm", "contextRef": "From2022-10-12to2022-10-12", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://jowayhealth.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "ea167066-8k_joway.htm", "contextRef": "From2022-10-12to2022-10-12", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://jowayhealth.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://jowayhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://jowayhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://jowayhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://jowayhealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://jowayhealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://jowayhealth.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://jowayhealth.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://jowayhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://jowayhealth.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://jowayhealth.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://jowayhealth.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://jowayhealth.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://jowayhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://jowayhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://jowayhealth.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://jowayhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://jowayhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://jowayhealth.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://jowayhealth.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://jowayhealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://jowayhealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://jowayhealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://jowayhealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://jowayhealth.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://jowayhealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://jowayhealth.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://jowayhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://jowayhealth.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://jowayhealth.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://jowayhealth.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://jowayhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://jowayhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://jowayhealth.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://jowayhealth.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://jowayhealth.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://jowayhealth.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://jowayhealth.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://jowayhealth.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://jowayhealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://jowayhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://jowayhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://jowayhealth.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://jowayhealth.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://jowayhealth.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://jowayhealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://jowayhealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://jowayhealth.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://jowayhealth.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://jowayhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://jowayhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://jowayhealth.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://jowayhealth.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://jowayhealth.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://jowayhealth.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://jowayhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://jowayhealth.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://jowayhealth.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 15 0001213900-22-063921-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-22-063921-xbrl.zip M4$L#!!0 ( "Z7357RKG\,N1, %^* 5 96$Q-C5U;-?$%-:00=I/2DI2R46 )#VB3@""[ZFN_?)3./ED M1@[AS"S.)*6LN8V]$<P MU^8=@X8)J,&SI.<[CD%,8M&YXU@?/O8Y$X[V7/KJR*!]:A3 +$S\98) M%%7;MZ@[C.=2T#@Q &:-166BTWGK[]JHUZ/=Q\,>P0;MI53;Y!UE25827*<) MUN 3L7^.J$X-4CI*BT]H-0G%B(%)DF=??SE.5&R+ C.2K:$#BZR*;\<)2@8T M+50_S<:E [!'_THFT9E.#*V(FH0>HCHV21$-M,$AJIWR/QXDY>3AKOF7 M+M_ !T,/)9.+CL[D'ABU#U-4/H14O@%4]F TZCW#]Z4' G(-),"_50N8.*P M=UQLU"R-#+Z2X8,$MD_)93*Y[%O@%B)PRR"+&I/',P-W'SK8\,A;0,D14!7? M=1D@W5.Q\9U@MVIIIYB2!]%\V90&5[KTX^KV^/@-4^38:IX^R ^!U1/ X-%; M8"@/S1YVB?>@/' C+X!X_-E;X)PR7&X"6)D9E.8";]O:$'ET:)#C1 >$O(AD MR:&HI9O0I4[ZJ&&;V-H3#_8 5?O<'72])=PG*9[CH&'1639%N&-^J#(](*X M3.'X-UW3B,75CWV%CG7?!%BJT*P!;3"S>.;:)A/'I"PE987:X[\3R *J82JB M%V,%+E$:2]Q1>F**YCP4 6P0CR^*/>Z.NO1%3X9V(#7PM$303,'X'2<\W037( Q>,-4D M<#&=9_MN.!MTXQ)7#.A'NO8J_:%A#H<1OL:CIZ/GNL9:.CIQ$2>%Q/KY2NWK MI#Q,#QY/EXZ=+YC- ?[:VBP6$&RYE*U):4Q""&G<-C.,B(6,&12V3*,U@4#X M,&#I))]]2Q=,!F6?X:9)L.>[I!18A2+T"8&%39-3,&ASX L3,W>*@ F\T[OG M&)NRF7G [, RSO*6C>4*@:GM1IK?SH-I'..@1B8])99MZM;/IOTY7Z;GC0,< MMD]P88:A@89&]%&8A] B'Z5A/'RR_QTYH15G,I7$AMZUBD@%?2#N(3*QV]6M M)+6=(I)&7]LVI;8)3Q(003D<4-1)-7R#)&]PE[OKJ)^8@.;067CL65_7:(]Y M(>FOQ,3HMNT"^F+TB8'5)Z2 H_)L0]<.4= 80A+M\KB=N;:DI_\ QPE/$Z7_ M_%O.28>"$<%_(Q2D)TA8!IL\!UM1-YOL8%,WP&6^ZF@G\9:BB#. 8^X[4RX\ M_S,7'B+)\9TE:9D8'[5+=_5:JWJZO=5LE5O5YE&Z7=HP IK5REVCUJI5F]M; MY?HIJGZK?"G7SZNH.DU54DB1 M]K.%12CY:8RX1DHV4B7.KAM7@"4'R5P>B^(+DDA:DLE36_59K,F2SP=UE*J- MD[8?DCV09.K+%ZT,P/O5F#,Z7Z*43WZ=CC%'W/T31>,C80QVIE&MM[:W&M6; MZT9KDU#?/&:#'M[<-9IW9<;PUC4",]\"4X[D#+IN('E_YW0779]MFM #5:TO M5?"V(Z3+3=(IIV"/DIAW##$\*P?!7K&?J2\?7[H/F(SSKO]@RB,'ZT MJ,%,)HSK:7@X!,R)%>5/<0 S_4GF[.:&Q5F9 -#,"U/ M)X$\B1I:@W1UC^V$4%93C!>GO$3KC2ZNZPU]"8%&W+R)T@6K:&]O?>$U;52S M-!]:04'0N6O[#CQ04W](0+)3'6"5;F\QNA&W#"$G$/90TR$JJT]I2(=%HQZJ M]# 8!G=WDTB,UQ.*VP:!V0P#GJM\OU5*\.\.UK3P>S!_I 8P2NU5VS"PX\$T MX5^B-G1$W7#8"W&IKF(CI WR\;!^=$2UJ3I"F)VW1:D@M3]9+%@L6PL0S2A_ MK=RI3RER=D*104-L%YP(W\QL4C#!%;&A5K&U.7J=;9G#:MXZDZOR,MP$VW-E MM4]*'-=^80H_Z2<6P#-1JI,7K.&?^0JJS2[JFY=,^6N%,A^'X9\A=LJ$V)WI M!H%5 D?X67)D!S$$B4"ODDFSA;F-E C)$F^(_[-O]3^M!> M>X=;8X&L[:)KVH/H_<)W=4_35<:E"8?.2?K(Y-@=@>2$PXF&4;]F$M9D!SZX MR%1LT]0]=I8.!>@SXSS>S:K;J=U/7B^'U[54(]5,"6RKIF/80^)NEDI.&EV! ML)"02:4<6]8T3QI*G_G.BO.=8/IL@<4WJV+U.!Z0)N*!LJ:YQ/."CTO=(G)\ M+% WOBG=?MN\'NB)Y<0IRXDG8@A(E'*2M+W5M'W:0YDCSW=*K@82 I]"6IK4 M)83.#3,V0I\76M8*_'GMMNR^%;^HM=.V6K"'DNSW&,R=*E]@3#/V;=+$W MA^U[,\77^$[R:XON8Y'<-&L^E?=]$?. MDN+.;(R-WB&:-J0"U"\:PY_5;(+ENK%A88U_=&=^J6:(O^(O)R;M5!\_HN6; MH"!1RA< ZU=,VSO3I[?+XXHCLH#Z(&7JH!L7U$UWL(&J Z+Z5'\AZ+H#\0[Q M=M%2"A%KUJL/PVD0+8$<$[#=^"Q\DV/%CXSQ>(/B/__.*_+!(0@\)09Q>K9% MD,5+)WL()-_P652+L$LP&!2-%#>)RGG;9"R(* -%\VWSBT:KWU^D6Y4^+<&N M1N=+E ZD>?NFR7G!UZ4-!O2&KGI.1.E3#Z;E L% MZ?]FU_]Q$58N%>P+1VD]K#5)>"86$"+ M#.R%9R96N#'ZZ'M4[PR7?# G%*=5[EJO /-*CZA/8/A[!&$'(&(A%6MPQSOD/L !0<'6,&SLV ;,S@:RQ$AGI4@/[7B$H'-B M$1=BL9H%@WU>P4;EE)(2^.ZNT#NM@/U+*#&].8U;33$J!)X?>]U5^.^SP!W> MNSH%\6.%:M\**H]>O$_\EN^Z%XYS._C[_3XQ>FRJ;=L&P1;_G5C46\:BQ):X M<)#-'KYG'W/%PA<@#$R(8BRP<'S7\YEJ@G*SWTR@K+(OU)2K9Q/R(!C-3O*4 M58IVY -4.6L@)2.EH..<2'[Q_;1U)D/KU?#?S9!YV_Y-V]!56%"K>P7V'YR M$:],MGJE4Y\.U$9WI2LEE1VVKN+*9KH^ZEJ&Z-JV7A5JWF>3]R?*MQ3 M9:@<="C>#W1^H=AF2S.ZHBZE=T'>-9=^U)7 ?&N5Q[+Z])7)P MXD(6'UU,Z,+S:IG;T" EAP7\3*Y_3W*]\$F/-1P";;&+E49[8P2K/:0:V/-> MM5:C'>1#%'!Y1 PG8\W%WO=M-J^1QRYF/!(X-H=FVS8^V;O$0CJXZ+$$APX* M[%V_IX,XCXWB.P(@4'Z@K.O:X *9 ;#=(G*[[1U%RNXIF?R>LK^_&Z/AZ]LY M^!#1Y"?]OY/^SRAK]2C7+(T%RV!GVD.DLET6-OD3F!C"3^!/[8#H'H*)(=1F M^'41V(\^[;&@VV&;(MA#&NGHEOC]H*C'2OMA8#95C(6G'O"8K M[?.?*],>S /FSF$_/61;K>WU V1:B BVUM3,C+OQA%QHBL<=LX'5<28^/3X,E_^<6I^J6=OEO,S\WGI M\2N(+9P9?XK8:HQ7AVW&SC-'[%20,&YHTK;I,QN[/;!G>>;XE8\)CU\+F/(!;VOP]Q,Q"T@ )I<\J)[,! ,(K945FO' M*K]FEJ'*KDO6L*MY8N-8FY?99G;P*+.-&KH4&HG>!BW8FPX@O..HZU)PG$)K M\8OEWGZ!7.2"N-@+Y"(7S$7Q_+4+Y'XO>]=G9F(6D#'D$ \^ZQ@"/,.0[NWI3-_Q%,\/H+7RL%C-S$5^.R]?B-_G%7U$XYJ%3"F]2 MG$'6)?@IV29@HH!,AY,=!9V+ JY4T9%[E5I^U!F: -='5C.&B7F M]M9^2LJ@T5W 'G,699;=&P ._,3$[TV9%SH9&KCO';*;/)CK@+A<7.R+V,V^ MJ8T["+:FI0L>0@!!&,!,;KG'A:XM-'U!T1YW\4%@&1YU1B@ MX%F#\)_V:*\(T@X#R+!2@/E1-G V:40-.A;%E@I[RT&B%(+C&$[ "]:/ Y0/ M=QD6>ZRPQ6;QV#%,#0\%0^(8$)# R0EIBZ5'R/[[D!=CIQ!-;6^U&&=9/:TC M0DL6!/)MA[F\ZT-PV=$-P(='B$'VZA**77Z.D/]>BE$_$HF,$(D4:L6(Q'RN MHCYQ"<+FZ+BC;L$T. ADI^%@G_9 @'Y 5[9I9EM"B% '\B5$^W:R!]Q@.RX@ MX@:#'ES;OJ-(TIXD_K\+LVQO=?07,K?W?K0W6QV'7]W-ND;F8V?YIT?*T5D0 M.P$VTV,,.ER94.8-SQYSXM7E =@@3\CV::@XD:.<\$04$@[RJ)",< "6!B ;(!&/,-KN_6>R$ ]R%D\AP5!+\08KKY"LF(K^V?XBE9/A]7S?--D]D(CGNKJ3O2 \N@H%WR8 M(^L_7^"9A 264;.A TMX(??D-P2",K2)2&H)&"765??0LP\4LVO!MK>">\'8 M+^G!@@U99CVZBI^K*3L4[1L&YTF "Q@@+;BE#^A4;4<7:/%-.2;.F%+X$V2R M!X "&9%O9[>UBG*I&2.Q?B[PKY#WN^R8":D*Q@+V$412FUFH+>A9_1'(6HA M)VMEO%\;F]]S+&(!0C[&L8C"4G^Y M'BSVZ**31;;FY7E;\Q]N&S[6$8=\E);*R-.QSUW]3OL2\0;?.>>FH=]_!!0C M\>8?@B%"EG(Y,L@D9?%FL52/FLM88L1N21-5$97W8O5AQ-Y*B2CN>CPD)V:;:)K8R&<=:_S-E:)3&,RS/?05 M'-/XV"G@FK::IGKEUUV O;MJLG&M#L\6; MT4\"@X*.RUY)ZP8Y_&('L$3UOC%YQ$+SC2%2L>_QHJSN!938?&7:BQ+54&]E/;2J('-\.;=2TA$CM+Z+^K\_]4;I'3:,TN41-0L."ST ;'*+:*?_C0/FO2U^U2^[?V3+FN#1^7:^/JMXSU>.I6OPVK-LC7OR3&LQI=_7+7S M)6=FVF?W^O?[\OMKZHAW9TW:U!I^ MOQS>J'KNIGGWX^S^&[X8W)\U>ZU;[^#.JV++/Y&:C[Y3[_G/BOO#[MU+F?-! M5GF\[>3*C^>UBY/,\_-9^HMVZV"CUGN4J]EN7LE7OYU+O8M6__A8L.1_4$L#!!0 ( "Z7357/R@.*-Q8 *QO 7 M96$Q-C#,M,5]J;W=A>2YH=&WM7>E3&TFR_ZX(_0^UQ!L'1#3B,/9X M@"&"0QYK'P.$)(_??"RI2ZC&K>Z>/@#M7_\RL\Y6MP1X\3'&N[%KD+JKLO+\ M9596'6ZI?^';+?WUX!%>O3+O%>*NV.21 MO([W62:OI\4!F_'L6L:;19+NLVW[ZR@IBF0&GZP='9X<=>^FP"?+:/VL9 +_ M_WWYX?A/!HIP/GS'>A=G[P?#?@]H_*U_^?X*/CCM-(OEX=3=*\!FBHDZ(\?_ MCH)'\^>O,B_D9$XDO.WU!\-])($-IX+%?"98,F$%_#Q.LC3)>"&3N-V2.?MW MQ&%?Y?)P>'[HU,WPN'6^Z,7 M&7VQT?G,J[W/0#X[4P?=T\N+LWV&;%5<+=YN)1E+2V!1#I3H M+SV6,>!YD3 17_-KP63,>#QG$;^=E!'CXX+!V_"/O)'%G$W@E]NI'$]]J>5 M])R-8.+LFL?R/R)D91R*C)U.>0J*RGY^ ].V6Q?BAH><]<6-S.&900'D%D#2 M@C0O^H-[I-C CP/V147[E+YO[6CXKM<_V__LVOK5/8'^4()RX%3;G=U7,EX[ MVNF@3VBWBJ3@$8O+V0AT!O0TG_),:6Q>)../6O$6M1>>BB(VY3>"ON)E,4TR MU%70:9GGI4#]?K6]'6RK_WG#CI/9#$>@T6$$&5\SWFZE/&,W/"K)DOYGN[.] MO<-2((E>##09>A0U>YP4J/]Y.?I+@,7 S&A#:2;$+ 7+$2J4 P-YC&K30 H\ M.Q%9!F;A4]-N<;:2FN_9Q2W1EMT.NRJSO.1Q@2K#P%VP%SFP_>#G-YV=7UX1 MC[T/7@/7@:F\$#,8Q_B_FZ1 ::?)K5K$$_ M>0[^*XJ2V_SSNX$%B0Z/3\Z[[+1[?GYU?';6N_CMU[7M-?I]<'5\:G[_T#L; MOOMU;6=[^Z>US^6>AGTS\HW("CGFD=$(>!&!\N'PS#QQ*\-BNL_V=CJ_O**7 MMX9G1_7O=W<[K_'KXXYYX.BJWWW;[?>[^.CEZ?^JS[>&??P_9,4S,Z=UN=%N M(7@8)3P+43E#F8'2)EF.BHG:/)HS<0?1W/A7#/*\(#=7 'G*LTVR9$:_ MH@=4'\,/:9;LJ4 MXV P=(IO<)HO0?NON/N_2Y##!+19.0UXIN)$K+_@ -14-,%(@OXJI/(P?H*#7(M89+!>#+]JT@WZ7#DWBJ\*;*([)+DI M2>ZS=4Y/5H1 H=\]=,#61VJX4*)&Q2&P6$Y0"5$F--@:(ARA'JGRPJTI3N)Q.2N5/>"P[C=B&*W-_XQH!([ALXISY"M6<\X- M<-!NK8\W'%T.&#KINO=@)0"\B O@HG!J9:&+FNYY.LWI*=44W(=28J7-1D=YB,Y^I@G2@D;=5H]X*FQXA_3.B#M@7:&R M+O<"GR6EPDPP.K@G&7\DCY>) EBG\!3EEN,IS\'*(>TS[CZT/LA^3=[*3+< M\"M6+I:)&DA8D#4LB< ""EO&8.\PB;B#^>)K01J 5+A!/LD<%I5(2<+/09+, M2*RF0?"#42+V0!TB#N8X+BQPQD.]B)*R;EQN3J42;Z6!DYM1CD"I1N#IA-.3 M%8JAW39(0;MN WPKO-6P&.;B(%9T'KSI=)TDH)!9!'!8@L*PW5/39-%8FRT MHV*=1/&MS(5G,& 2E2"D[&0UT42:(;I&6V D0I;E4B4[]BU%>"(QR/@[9; M1' %FCBR'RIW?WG ]^L-$^8M2O!B1>S%]22#M$/HGY<)H$'+89+I_<)E#Y8M ML,$3;BWM/2 = Z"IUJ7RI(J]K)C#,C&2?Y4ZB MV@-\*O+O)%=>)X (F.V"7Y*\ 6L%L V56 M!^P/K"1 7L0V-_6.QN%9[P]#J#_]SF[#_*_QLU&2@ZTX$\C $6 ME2%0>%4=L<:?PRV8M8& 42;XQ\V1 (<'5*:T*)^HUPTT(:&/G=+CW!:R3K'C MGZX:C\O[P![?QQ$5B)>@(AW*<^.=(4P4&<_F#9F(\AH3>2=R]2@8,Q]#A %S ME.-<.[[E,386$AV4(@7FR=$Q0IYBD'LU!-2=![FXLH"\*28LM9@_QAJ,F*'O M':'=JE0'/7 );BCSX(U)8,T8,0APZ4+A]6M@,W(=OS4HQ_.+G""4S1(H+<:O M5P_+*2>.);()H0*@3/@Y,-7\6ZY\.\$8CTO+![3LJ%5PR@S( C$K%04(+WQ%S)=\W,S?M*33(R,<=7IUK-%^6-@)%(PW&0J4.[9;! M[#@W\E376TP1Q68*W@::*I[)R-5X0+5C>!0K/V- ,XZ(B_[@B]OA/[Y"?$^! MF K()ZY"?'KY^^^7%S_*P[H\S,Y,:081=@B_.H2==]A%@C4GL[?BU;"R"A;W MLBTR#VW,C?B_$GE+PBAD(B5D&5$M[ZR'V+' Y$-OP9$C*R2/=#4CKR0Y+: M=.2."_3/ND0\%FD!TLE=]47YBURP8S242,W=B\?5JL4GEY17+4F7JNX7;6-M MP(AOH2I(-=>*/G';=Q *R,AQ>DH6E1>G&0D]^5,&]3T*50VOA-(J"[RJ>7,8 M>)[ :(/]01"BW>I3O.^P8]R'=T*_7]0Q#." ,SVHWW^1Y=C\P69"X!PU([$E M,@O=>9I&$!!&$3B'B-]Z=H&*8G,'9R!*]>\S$"WT3S$0VLY98B$,N:$AF ;^ MED,W@(+PP202D4VU*D"<6J@>;E[5\@S5WFQ5I;G@1LXV36*O[/,,-2WP NK2J!VRDO\D0 M'B>%HT[P>>NRA9@I/?5_H-48GJ?@G3_ M2],B=%RU:5L8M-&]LD6V&.:]4%&)\GZ=L!HP'A7WVRT;^,V73QXGC7'K,K!R M9![] 6Z^541PJT50IDU;1+:>< .OQ 56:BC&VU_![TS0BBU@R[S-!B3<0W*T M92=&A49]D>0C&2W=G2*'INJL3=59M[$]I4 -L^+^!$=,IA-2SY\YAZ<=QG=B MCP\KW>[:*NW.EZK2?HDV9&_%9JT';#A/89W'&>C6^(!=\)E0_("D I:^6ZG3 MFK?PFQ\UY&\A9KPT<8!2C\5 @'[JP2#+P3=L/0X6'8C&@WFUJ?;EV M2Z<%&F7XFZ_YN*^4E,)URC-\V55'QR^GD:8)I):0E$KU3VH#8=D>I?=,QA)(YML!J()KJ;E"4A.K[9#^_Z>R^>6-8>M$?U!2* MA#CC'[&IJ;)EN.[Z,;Q:1AQ4NQ=R+533V[ PW'3L:*I&Q3C R@F+*%:;(RYFA1 WA!_ T*I5VZP8/ M>*M@=J!8B%"U]YF.$X6P?2R"% ,!^61>Z6M"!&9;836@\5 /,DC'^>]9C=6) ME\OW_>$[=^2E!H>PIPC!J\A2490@(7$'XL<(][5Y\[2G&][VWA(?GOGI!I@) M0(*/KLT!';M-@6TXY=A^SR<3+K/5>%H7"R ZH*7_J$VI P+$\(9(JMA&." G M-F-AP/E-+#6L[VS09C'U\M"G$PD>&YSW^LZK#;36W/IF<8?GH]3FDMD,PBUP MKQ.:2@VFS+ALF]T+8#YP6 X4EF&# W;X_LBDX7B(*L /ILDM%C7H=RS-@F.G M:#/C=W(&84+OCAG4%(\!0.>BH9U;Y=P3:GFJMO*L*,=CMR^]X?650]CB8\!< M(6V<4R.8:SQ4ZGX?9JSMB*XHVWY2L_,G%?.?G[5!#G 9"X)#"^UOFFL("K*E M.)HZ*F;)3?4X@6Z9+7-K-N +93;3_<:UWHWB-MDLIC(+7;_$0EW1U$#:%6<"Q+9S:!%M Z M(9')),8IX),NS=E(5=^[?H8J#^G(!_ 5Z%.7-86,A-] 8$\B)C'PUVH"N1*5 MQ])YB)K*ZL&T3GI*;[ITW28*ZKWK=R#';%68%P&IB]Y,L=,:)&Y7LQQF-"W& M14A_1;IB%^!IF_J"=$I07;ZNRH*] )^Q+=;O3?&JK]5-GWO,Q1RF6CW7\!>94&***$,05RPPW01-;'K*ZZE:/">SD*X3ZN=W27LUU MR'BB]CIRN0P5?=;>U7^_;%KU55.Z!Y1N7_XHW>K2[QT1HH@X<>-4[KZ^-]6R]CLY$ M P8)U0B3,E/=P78..P4!'>.RO#JNWAIV+[.&=XNEZU8IAEIU4'O.3QN^&'_P MB"C8O^4+IF<03KS\[&MCL:>M&PVZ?W0O?E2.VJVZ-CU<:S>"Q2J-0>X%"FNR+#D+4UL7C,7 M_\!XEG!$-,B766P[A[VK%@![$C+!AA^W^A5#IM@6;\OM2VC;".R4<]5;A,?F M@.T5HT?$K:W^=IK,&+@3[RH2!=(0*]N1')!%N5!QA0:^YC+.B\I$VHV(NU3$ MN;J$PA;OO49KU9.38Q.BKD+0A'0@%X\0+[H/G1TL\+-Z8A/1HXQ=I0P@9RGT MJ6VNRU^X8%AF#C"""D6J\L6=5_2\I](RU2D?X^U$)J6$E&,BW4$,(='1BCLQ M+JU;Y2$>RLX+D&.2N9-ABHA.K:H^PU,.6%M"O<+V*4R)QWA656_W/8W95'0% MSPPV*XN8I5$R%T*'4$ 9<=&H*I3:? %UP1(TZ0O[NNI")5'D9VQY1$'\VAQ; M?KRV! ]0E^=7I]A=&C]2/J]H#.:&)6D$R#($[5 YN]J]2\9"]1Q;U6--=N[R M5EM*]AJ\:C[<+WI3K4R'>SJR%-Z8$U43B1=K@!VG22XKER XPNZO>JMX1(;F M&IQ45*NS@ K&32NL-K!3U*/DFMK04MW I>RVX'A0GBW4W?S!J)2.\"N:(\^:F[O=M12H MGFL+$$M=+6OPM($57R-K\0WK&JW=VR.&Y'"U8\8;4>P8Q@D;!J%.P6M+<#BZ M)5K=,S3[E]KL-4H"IZR]O>[GU4Z9=+,N>:?E>)&%"/6A3[!B[X!BM:OV;AR5 MN2[,NX9A]7B[Y9V[US.C*"GRZ?BA.B+XF Y6:J54#>%T06#@]2@^;&]H2?-0 MNW4R!Z2(T>(:SZ@K\)JI,MEBH4\5U"662=06:_-U!,]0O_8:P@J*U-[S@1HR M@U!1 W7>B/P\KC^[]*(_J\NC>C_+H0W3T2USTBK=G]WY[9TJAQS%> M4Y<*=9W;+ D]S K.QT9++)ZRR[X-FSS%*.52J&HP65$6A-?H"AP*H( I@X4( M"X@'A@#@!^A0=0LJ[V1/"=K[4;PZ9C. ;=KOQIXS?>.-_MHT_.G[H30K('OT M>-&!H%L_NH!0(Y)C1 7%+;;,Z&M'[^-8_LTM LB3KL;:V!A::=/'XW4<-/703#I)]'!67,J@T4>*22IZ:V%L0< M9E:\])C6JB]#]ILL)9W!>$07SV)CA $R"]T1''N<.(2UUZ\WV>[6RY_,,\T] M$DO04[5WHN%,F=IX5)66Q9EF0O5(Z5]/3#/(6;7[!HE6NZ[4@B-S=]U&H0O? M\&""^Y:/$U_E)*V]09Z,.+ F#-:L/,$W=N7TBKF?MN)^T6NNMW\A-_RM%N%/ ME3]IMP:T97^,B8HN1G3O=$-X/46F/B&5@JO,^QIK;+&+$%4-KEQC_/+G-_!( MEI37T\4O?GD9X*:]3KD"KS_I8YS8I9;ZWL],L\[V]/5_D_QSG])2^84A; M@?8O'31?5NQN*;Z&E%-O!6$-R10H;&:&)S\"%5!T* ]<)%<5Y[D?MGTA^Y5+ M%!3>,KZ[_8V)Y=/R'DOEDZ5\KWZD?#KE>_5L4KY/UZBO[&1Z%^Q#;WC1'0S8 MAW?=?A?_GM#)DRIKS.(DB MGN:@V.:G-=+'^^]Y4G^):_$RI]?;/[GE#,_JS]WG1BR9>SC2X=O+BZ&_TLU< M_D>HY<*WO:.M?(OU\00[.^<%/]SJ@4WA.T?NUJA'+:>1]GO(4&[&I^)+4S#$ M-! \'81>/"Y9-%/PW=R>]3 O]>"_L?:Z/LZ][S0%WGX9B4WCN9<%V*5@V+/. MMYB(Y/-ZJIZK][Q>T<]_?[L]:MG\]G3[T^.7\!_ M%?[/T[.79Z].GCV]Q_^%;^_)UT^?OWWQLSH]^_G5R?_<659E^XUZ<'_3JK-\ M;1KUQERJ'ZJU+A/^(%&GILZ7=^"'\--WO_5W1VJMZ_.\_$;!HT>J-1_:N[K( MS^&#.C]?M7>>/7W^[.3#*E_DK3H\>/CTWG.8\[N/_[;4E*VI[SS[JEPTFZ,; M?06LZ/CUR9L7)R_4\9L7ZH>3T[/CLY,7-[XT>*]=W3=FU^8=3;Y3)/3?.'D#!\]A?8\7RY/5+_R7OS,C/XZ_L' M#Q_EY9UG9RNC-F[1QBVZHD7#?^:SG8172'?UEQ:&^:K(?NVJHV^K>E/5NLVK M\JN:/OFK:E:Z*-3"*-VJQ_?OJ].J@[$.ZTR=MK4Q;:)>Z4;]:,XUS/V-N="9 M3E15JZ9+5ZJ"P>OY;%-HG%"MZ(]&7>;M*B_Q _P+!E0XB=-6MSAM&47!L/CQ MHM+P,O@XRVN3ME7=R)R6=;56+6R::BO^;V: (NN\- >)YD3 MY[/_E!/7<+PPT/J'J-U 3";/IX+.& M%0#_R5L(=$AA_PV=:7R0MGVQG=AVQT7!.TC5P"^T2JOU.F];XX[_"-TN5SE0 M>06$71A3JJPKMN%AG7PS\<3E"M>PJ2X-3H6..FC"JL[;'#<;!MW4U46>\:G7 MJC9-572602<&AMF+B'B^+?3EV#8F\$1:=)EAL8?O5^';M_,9Z#_N!@,7-!Y$4$ "WL!3)".MCB,&8:QQE!<-D'0L2/)@%*K!V!3R :X$9-_!QK=95;?CC)O_0 M;OF+A5GRQWY2( ^,QH/O!30)3^ SX%@%=F?>XI3AN8NJ'3#*@7JYE%4D_(7= M3;O$S)@U_Y[^40!;U@9%),[6P'[E@?'SSY+^14852$X<&,1EE@&7-CQ(3YG@ M?'!'Y!D\2#DHB,W&:!29I7^>S8 EJOVJ>D^GCMQQPJ<:%M/J<]K?VL#G\/1&YQGMD8YFO>"A8'=)G]G=3$3(7Z*F .)<:CS$ MLJ,\*GAJ0D44&TLP+$)R)H'YV*,RB_=@#HY"75D:<+4:X+L#]1/2!15LJ+&_ MJAOT\/Q;3$[RGZTBX)?:"L)$$3%^@0-3&FN"Y;5E0&',_C3]#^R$W>3.80>( M',(AJ6X,6W$P6 XBP M?.-(O6_FEJ"RW,-P!'(J6%K^<#3@XS1OK?^ S[IA' M:PD.6[PJJ[;%HB0]N_"F)]LM1(+!6A.Q1FE8^K^RZD!3K(4[(J'3BEP)AZ(' M8=M;_=Z4>R"XW>C_=?>N^BX'\_L;]0[.U1$,\6MG8&O@3>KN7<%XG[YX^:.= M!@]^MZTV\,A#?(-\LJC:MEI_HQ[C9PLXT*9VGST'NK]7#PX>P>3!#LLSF,*[ M>,2!2_ST'KQU9 *+VNCW=_F$?J,V-.MP4H]'YH03_:VO#+;F'NX-;\=MIGJ@ MKA_#TCZ(\_"#B-\7('X/U'>B%YW273KGBJ1&Z&6$JLN?>!S J[+PI/>@!)+% M^'UPRN!8LQ!FV&KJ;: R#,J:C=[2V121DN5H\I>9E?+$A?C\&@XN* &[$FT= M@>@%UD.R.%E=;8PS.9(KX*_\ UFAV069H%J\UR90WEJ[QIK1?GO#1@ MUW,4&"M]@<^ =U>?.SMEU(K% PL;";;DM(^'XB5!6A9&-ZT_16)'DOD?HF_Q M42"X9%, Z:RD&(-TKO(31H2IL F%OE)>\2Q[*PTGE'A!]=X D1&# B]F !G#J;@:,T[0G2$CSH/$5=>2 M9ST"$K,$=.]ONL4OP"&X=7F)=C31CF"6;>R7]5&R,VC/$_&OOF@"==O@BU%'35P.J\G6_=+ZOU-_5]7U=T:28)NT]UV51O# M9_SP\-Z#^_?57PX/U8-[A__]5SR_J5A-!(' .6KA0?$*)R1=7_Z@PAS@>_I M-BDX/8QE$*;BII,0@SN9(S!^X!+S<&M,@$&59]B8B'WF8!FP*XT[SX5UXS,^ MY]')C+ 5@NZK^ER7^;\#A &G Z2'OSO>%GFMGW '7Q:AQB)[%'?.DD\D$'R2 MU?H2A Q0QX#W?AXC+3 ZJ%Y8GV<:NX?[=<[_KM[!R M(3E(+MKC*2@VGUX+B%F<-/@AGVA&13$^QZ&.?Q/W@ M4FBT. )*]/;"SF\_0 MS4\):D1-:X"/ETY[Z!*,,#)0''_CQ#A<2XZ5!^;CB206I-*+AA2(#>+RS\A0 MH)BOA ,9^!T>[C&X_TTEV^(G!83(! (TA4&8; UD735RW,4UPG'RMK%! 5AO M5Q(?A@$'-MOG,YD_O6FO6//!?3&\B3/)Y+6!8S:KO,L,.UG'5LFD<>MBSXXH MX:-5R9Q#5@V#["BUG3HA2_9 _;-'#O+MV8T2+I.L#U)\+\LTM#L76XI;=*CQ M^"2$H:6AYD"C"N>$H0CP!18QSLL"$WZY[ HO^ -3#@W@G&QW8$?=$,*NXP [ M'N46>#(!CDO1&HW3)Z(#AALY."2;HJN!OOZ4\#)B?6@%_ZC"'X"IY4A\ MH]HQVSTX$=?!5A\>J;<;7'SS#;Y*#M&1^E$7'7[]J:#7ZZ][F"H5HZ[W1Z;# MV8?!-M@-.%)GVPVL\[C6BSP]4F_TVO F@0R&I3^,P%?[*_SF"S!\PT+\@45/ M,.>-3KQ364@E_/CLLL(S_QK]_7>2E,!!K>JRA'^O\HT7P&3'N=!2*4.T/ 1A MEY+7,*;9+R5\[)0[1WWZGHE\A*9FK>MM,N+X72=!AJ#?TKB)6=,B^AW9M"#7 M$]J6,9<'I2L+3O)L72C);T[N'5MP=$0:7I UC?Y_:]8;BC81YD?9)*!'8'5+ ML*AH031\XD4PA0?]#%RH&]0L6,RRP63DD78B*GA'+R!4XL0^KJFW"E9[=C14 MLTZT6YTRG]%<>V;",R!38Y@]'P9 MSB/%$"!,]!P\RCW0.<$!?CAR@&$#OS5UJV%7OW>Q!7%OK9O<.Z$V_R@PA:Q[ MR::Z@&<"K"8"JV**!I.JZ>51-13+Z _GHOW)+N.>K+7&&O=3R5OREBX_U<3!P8"TAOS>V8C9\:.,+"K2<22".BAP3#VU4M1 MOW4E$LD;;"QXD(+ST=<.T UG!.OJRDSR,TC\5\7N454T:)1F[!8DH+E;R7Q& MLT4!8I/\4"AF%6)#F'$$+]9H1G.0#N,M=;6I<_(,*0 IRB:MNIJ.B*3V=0L0 MZ,&@,+U 7_A) L_#F%6.B,^-"JN)T-;-2[")%Q_'V#QKKP#/VP"[GH?)7@-? M(^1,!IL"5Z8'B 'M:R*BV!/.6%G9-Q'X*&$SGQADOYN>10PG!B_[4U'S#J9I#A2QT!T7D89%B2+JA8,-Q^7&\.S>4!.WB+ >1GF1\8Y5OME MXAR"T4PA+B'/B= -L]-\"D8ORVP CG(RKTWNC6#!>E>I@8AB#J)9WR7(+RLK M-#90J2\I:PWMHX33Z\)).V;#P'S:_H9H+J/QGCF"<;T(8A, W!GR#2AR0D&5 MJ226RJZK"7ZK[$^#=^#&Z=8^'8"XD@^HBY:R3V,D"$FSG-H!/$?X:S\)D^VB M#U*!$GHXCA+,I/=2=*XH!<;3:CYSKXAHHI8Z+\C9X_!(9$RCF\&LG>0#>%<9)LO<<$.%A5_4-3%(\])J&G< M#\, 8DQT?MY\ _$>CPV;L5?H76(&BL%199P0 )5&@&KRZ7APHD-!UV.YC,V M&@.,8 %KK=K&>3%PP(] :>G:PK/A\BE6B[MCRG/#=3:_=J8AY,5FH&$)*_RZ M$6,>!BWE&+L<$ZJW=^KUB#6=2^C7BZ[@,@"/E$2SZQ,$MJXK@%_( : 3G[:4 MABY'3_+T$"B16I)0F=-)(S5/\X,S75/H$<]R47RZC( _[$Q=#Y$^_ (^"_A\ M^ 5\_J,,NZ_5FXJ3%^'H?VM+",%V.)NLUPM+#;UFGZX=E!RLE$#*TK_-CT*X M(4L/$4 ^7CV?6>N.(X[.@FG"0/))%)7S.;CR6\S7DG08LD&T2#BK\#.C05 Y MF 4E=[H5!P9/38;5A6CJ^'U2E&0 ]3MHRC7;<6/*XSR:8R7\)+M1#ZP*RR1 M A5G<[VSH55!X^Q,T&)K; &3>SWZ=-%T>I%BWDK&C D/%]).+Q:K=\3IZC:5 M3:B3>3IC*XS01^\?Q&MK>7&0(\%ZT]99#3:0=V8^"X,+XQ6*'MD+[_N$8WS7)*##M1QN046AX]%!@*%Z(KTV( H01T_IY394\>VVNBQ$\IX M<@PRV_^@@_")6XR\/%#/K8YZ88ER&Y8R.+Z'V%[D'Z:DB.,[*LN7U'MW>(F! MEVB [\BDIV))"^F[N*^%"">JM+W//"BY'F3(361_[8\@/<3F'V_(B85!P)-B MT-J!9#WT* (Z)VG":EL&C4N&$">*RZ%!D/\%%'(*"<+ M2D)7/C(/]!,PGOWGX%#7DC\< 1U@;S+ M4$F@'6?#5R/;QY.AF +YG\X[;U8@-HW'=I$D DZ";8I<9P2L?P-N^(+5BK*_0YP'1*$5*W(/T7@ M,T4+U](5-\)N+E?<(--@GBLNA\(R7; PHN,""IQ6T$,;E9H?F$N7VFY@ :(-\G:,, M0;^L*_-4@ FLKMY05 F38Z1.J/#I??[509Z-I2_H3D+].51!XD!J$X.?.;O" MUVM)0EYJ?#;19^IJ70_F_OH+S"TP]]=_1IC[DVLBVQ;K0,6ML$@+!))XJBN/ M[1WES+/0/K?(K+G(JZ[A] #R!"PRR0>6*OFD<@5$SGFMURH8:3YKJ++IJL%0 M=.G<0TVV'50[9D5B]G(%LRSR]X:;#RQ0=\)2,.?Y=*2+%9@MO[N-%4\,TP=L M'ZO=[:+0^>".6M1KE%\@[W,9YK)7&\*P-^2M@7W-\M=M)(&4?MFH J*.4KTD M%/(E+!@Y!40*;H*)X&7F4EDB%M ]?@D$MN8)D,,WWNC4E0U=XJ[$(^,KFV#X M)0*-'*+>$+F#MC 559U+[RN701EW 77@S\*0 Q8I)4P212B!BJ'0(6-3@X/! MP)+(*I(TQEY''P<.RU@Y.8Q,'C?%9*P,8,3&*0WRMQA*1RMWQAQ< 2P#FO% MF28V]2_O52KOJ/?V:[&_N++6FV5%CGG.;Z+S?F6W->&O!E-,@5:EJ1D"#[-: M[$X^XAGF#OXFX'BOV.V)>LV; "L]3B5A#+TBG3I7ZVIZ18)Q6$L?\(*'S^)W MC("!\YG$++0Z)\"HMOR?]PG61G6A.%X8K\CCLE(Y M+3^@=0NXWH,S@J>X9' M_XV("G__Y,H'?(]05* B [B#%*N #8(=;>L, @8Z=S0%#HEO&R'0;WS-@E,\ M2\H;*&VID6CD!$VAUNH]VS!' ->*1PL2>[%3L>2?%<6 *_>+@G\'#N7.S 3J MAD8/]A E/ J^[K>.A@UFS"'(/(A,DMJ/:JV(5;7>U3M^T*K40C# 2OT\P4"A MDP68E\.W,CF1MA:RI_@E)=)M7,YM/SESKZB+E?L676?:2G(K:/PT[6J"G*M) MU+V'F-]4J@-+BA"L%\G@4V\QZ&%M3Q\$V1&S&23OTHD'W@,:$X(WQ/V'^%T_ M',*NEL\-:J7E: 35BQG?=_]LJ4+4 PX!8C:9X#=BW8I^M*A^T .C"OK.?LDZ MN9KY'X!H6W-211"$[[&;5=>8BEOOPHQK'(N:GA3;+]M_C>U_B(E^&P-^ *N6 M%X'EI3E?+%&L8;CE9QH\+LEZ]06=NRD)A1>Y6 375C>XA_%I[RPZAJHZJ,OJ*J@JH_^C*CJ'\:;SA_^\<"G"SNA>JLS MJW;<,C86Z 69D_3"PM@\:+S_@NWH2 ,E_LZ5J/M%F!7(LFX;2S:QOES_=RYI M"FJ?+0R!H%EJL@[S$\10![U]HJ.\ M8P]#Y1RW#5>Y,_MID$_NK/\XZ8RW)=Y$\(KB\3'1&TOCZ)FUUT?4U=E.-J%6 MF*SM)(R+WO'"MO[+\L;E4\@@$V"9&_)/%:D-R6+S4BDC2R[J";Q3+!=:Z?+< M0M*6()29A@Y!E''$G(GQD+R1GL$1X2( B7TH(0\WVMT.L^&G?.9SKM^RR1J# M=C='+CG,)3%SM),#UY\*R))!:SY@D_Z3"5KM9M/J<@*IF+X @\I2 M\U9F#?O9XP4UP0H8_[*N0\ /KI<'^0[!O7@43$EV>:Q#H1_T;1SSA?FU$RDA M$IH9>*&W0:/VK04P%MY**OQMF/[ :7I$-SEB.#2GUELH]&QN_]BM;,&EH4&^ MDO:UQ$FD$LF7"KK52@+@CB1;GO:D]S1F MD?0FAAK5BZWX2_+J3(DE2Q<4K/-UT[O>2ZVY:>XD4^QYX=,3E'5744L(N_?. M)=QUYR'+?8*Y8\J%^<-<.>'ZPI"EP]=3"=##M_FX3LK-]9RK PHJQ<>..3;4GF.%/?!L9VNIQ MFX+'D4TV+7@QUH [\%S!OE,H8;0%E.MD/C/K35%MC?$76'@;A&MC3+&4C'9I MA A"C KQ=XO:6,CUNBJ2XN2&2# ;G@,7GKI7D&$2-((;PSRIV@O3/(YL\S&Q M@&0,:_N-^"9M#BVBS M\2G;P[HG@*@7VQUE#:/WM8( )V\#-A>KL7[ILG-NVDZ_P+1H=)?A9+2C0NPR METPO1&RMN;V0EG1B9-.\HWXZ:'.*N>O$A#6#0:W#) *GI\?ZOLQ$IB-9UHUE MH!NJ2OC,\-G'7_!9P6=:%$E4 MK=$%>I91^)[L5DV=?/#V64-7GJ)S%B2K#A7,K:#3 (UXB;$+UEKP\U>5QJ88 MWZY,^EXN-G_!N<^W$ZQXC&"%6Q^PH.!_\!NT8GV6UT@;+VIRQ:G*5]S>_9OB MYX)L@+BC!EN"?LF@QX?UODU= VN0 AT;$X)ZWL:..R=:F3YQ1/XK> M].WPK3=RL 4-7^$2MB21RN*FK3O;A([R7UQGYY$K609P++">PQ]$FHK_+OG9 M2ZI$Q%N/&3Y-Z95H;7O7G?_WMO'K0SZ$="%,@7\%?67LUH]=:Q/WDB=9Z.XY MH_S/S"S@AP0-^0R=ING85T2+FFAD\TT]7!L*7>*1 $8[C;&BWTVKV^_Y/$;/ MAP5GHE[4X&K#?T_:%%-Y, (HWV3TC>^O1$:M-P6"&V7756FVU.[ !,];FC8# MHGI:AN=M &.))#&UP[8-BU60#1.0(RZ5;E+>D>@(9'.AE($"%J4Z@DI'+OV M71/FLQ'=?OTBX[W,"PFE&!/#YD6U3MB=9S?&;=\ MW_N#FCM]*_6LH8RBXEH]&WR,U]01-U.\J3OPF21$)$&ONA#+ MR8>@@?STIC.!&]-*&0RQ@;CDG-Z.P!^YYJ,0[[*KR[Q947BO?_VPY'%P$PWJ M*6,S&B2K1F$M*(<,K!U&!/4P$#5H,M(P ?Y1 !NW]ALD M%-_B+CB!F&Q[:9&=#0S07AI3CKS/PAV&M'93 MP6[65GD3=_L($H,O87=FV[DHR./8=9DEYS!]B(>(YC^?32R 8MN+AI#15F;[ MI\HANPZ@_N0+H"Z ^I,O@/IGRL>EJ&8%P@3IP M5AR)*A_Q"ZY2"@T0MPG8+I\=_AK[ZG?&*0:^0[9G4_<'8M0N4%1NGX(+BER< MTK[C0+TE(X\O<"6M @8@P3KB%"ZKH$];9,>/-P+;>Z_\"<(Z[P25B9RC-]6( M7>K-R:5PA;\PIUS M6:^A@, P#C5.^4@5;7A3SWZ6M#W!L-M9<#F>]^7#&_.<:9CJ38Z7/4UU.O4$ MH"[D5%?(#J'\Q/F8BZIZC["5,P_=#9CN$0]D,%(AB27+/ DQ?"W-W*$Z'>_U(5^]A>GF\!]%^@D)"-[<&"QAW@!-.8-Y%$2F84-;XRT6#,R7Z M;.J>U9C25(#H:Q:K]U?D[DI2_8B[)OT1,(R+5\PZNBT%Y;!W@NW7(7NL7F&# MJ9[GNR/3C?^%US# ^T-:AFX?M;FCPAM;FA,^R#VQ"->8]IXQ4_Y<^DAYEZZ MR29(^L)P\P^P8-H:(>/$VUUK_5XR+1$:6R[S3%]8@!B,"XJ(RQMMN\A"@_A+C]0P9 M]UN/VY'#B5@D"+6DE]KQ>S^_B,M.Y__*2,S+ W"DFQ3.T<]&UT?JF)/#CSLX MSW\F=.B,,NIQ(^:S+=T3.*6SC5?O!39LS#3Q\ N0>[;XBKQ-'(7MAXG.^]1F M3W$.MN3D:]QV2HJ1" "]C'F99T?#HK+ !6P,K<+=.)Q2J$)3$4U8X\K@:;-! MWP"S<,)*PAMQ+S\+[G[Y+^PZ0;9J]K&2K&X%+[M%SV?.!)ER0Y*0$<==OLF$ M*X_)B$K,#*C)>HA?A!7MDLQO&ZH';3I<#0D8MF@ST)0*?1E0T;[(^JRI;E9D MF;!GTF[YEH1)3]5=17P[TL/_ ^;_UT$D=DZ-+CZ[L_W[RL!E5=,!XK!+$EEZ M"+V1H3IAWOK+92C[<*^$X+] P1^OX>P@7'2;4DVOT2AC])(6V];6WD["( -J MV34I4XS4;Y!SVJBK(U^"1Y?(D%O$GW]^K'#%<&,QHH_*;7>>_>U&&[O_T!7F MK@WIC$3>*+H9SV[WX;C,LW:%D[O_WW>B 7'2=QOP'N#+(&A'HXU$[.R.8Q1* M_G\8A8KF?1,DOO?\[8N?G^$?WY^]?O7L_P%02P,$% @ +I=-548FEJ)2 M P P@P !$ !G='9I+3(P,C(Q,#$R+GAS9+56VW+3,!!]AAG^0?B5460G M%&A(8$I+.YD6Z+3T,KPPBKU)!(KD2'*3\/5(LIU[2AP@3_+N.6=WI5TIK?>3 M(4,@X*'21FNB@%KVB".,= M=&]!)%+=7'5FN@-C4MTD9#P>UX1\H&.I?NI:+(>["5X;:C(]4PLG8?';C?Z) MZ7A&)J.C _UZ9.>T\5'?T1>7=7II?J5\^N4;_V"&">E^$^?+JX] M+LB!S0EGXN'1X>$B\MX2N(2==Q4OI!G'N+M4P4[9>]@B>"6VHB)?PB9D1 M%L$')''/@F7'4B&D;6P[787%V=*4 MV^^76J0%N>+^#"&@IB =E"BBF/,UZ-,T]E M(Z4PE!LUW[IR1*Z@A_QH-5T+M /-W.46%+:!@EX[Z)L'ALL3^FY+J]D6*2%. M^I'1\CN_NAM%X%*"JGA-96WTK8A,01EF^W1AOO/4F7'TRX4PR,71 2+_HF1. MNU5+MA3@_['6"Z>_6&0Q(V0^),7WZB"U;+E2&236AO*QBS&_TB]D[*4>H;@O M7/*P,^&HCAM1;:*3>:95DICO0+4D2MX>26RYGC?%U]O@;N%;:->@LPNYN/]W M";J10X ;75K^*H6EUZ9Z(J/&HA#.395S67WU=LNC? !M#H7 OO%M"8O/XU^< MAY>I="!+K9T819R$$PUQ&.%ZM#V=/S']M]YK(&*9":.F589BD5)^[->9\S\V MU?H@/P37"ON&W:,+UH-O:H$6R=7L\C=02P,$% @ +I=-51H$"V;]"@ M@(8 !4 !G='9I+3(P,C(Q,#$R7VQA8BYX;6S-G5UOX[@5AN\+]#^P[DT+ MC..)@UT@V4Y(345#N^ Q]=W3\/4;C\8!ZOQ$:,_[U?E[7 M^YCGS]G99/+Z^GI$V0M^9?PI.XK89EB%BQSGVZRN[>/N8_6G#/^4)O3I3/ZU MPAE!XGC1[&R7)>A$]D@T>)U0>MXB,5)2L MQ19W?'IZ.BE*E=10[E8\5?LXF2@[=/CZ?CD^&B7Q2-U\(LCR%E*[LD#*IIYEN^?!4I9(DD85=L>.7FP MFTDYG\CX"25KG)-8[NA4[NCX>[FCOU:;K_&*I",DE8(/L%VGK;JJH(EKLW>$ M)RR^I.]SK4=[LB^^.SS_'QK0C'?>A"7+FY37&:_&I99'L\W%:'L8R_(&SC76W5:N9I?"/ M=%7'EX=%[ (PVI)QDK$MC\B;>J7I%CI*E:--*A1R247H^.MB]&.A0;\KU7\^ M30ZU..AHL03:;@C-EZ)&2PO:Q:ZZV69*]7*S+(A.MAC2^UA)D-0X[N +L>-8 M[OPJQ6N+?:W<51=;;:D^;A4&T= M;C%I]'U#$Q8"IC&8A(;6T\!^3]:)G%JD!7E^2^3&CF$,T+L>^CMMZW.!51P$ M-$,<@K-%,PC549XXNJ!TB]-[\LQX%SYMF6MJ;"9U6)J:H!BQ& /1*+6H%'LB MXA];<<9.>+KOA<)0NN8"L*JCH .?B4I-;[)67Q2-)4W@_ M'] L8E=TP(;UGDQE4$1 ]H#F2DB M4!42#C:7+W)U+I9) QO;T/N$Q[#=Q4\M#A8AW>% BHHP).,\D=2X#='#D*%T M30]@5>=&DP5%C-T;R$HI1X7>/R27-!Z$2*WS XAFTXY')0H0CK:S/C2$VB<8 M5TD6X;3T"R2S+>_D\W*;4"Q$S,3)QG,YI3':_D#W8 M+D/GE@G 9AL*3100%79G !:5&!5J).1>P+CCR0;S_2*)>J8*4^@6# 62OT M0_E,"F+R/9ZB B1K\$+<11R+ Y55_UPGE!R#[;=JW=+58;?-E$48$$FP.X"? M2OE!?4 R!MW24*"9OJ&I4__03(=",PT:FNE[H%F^LD"@.7E#4T_\0W,R%)J3 MH*$Y>1%L4.D%&=.J%9B#+#Q<#&]]L,@ N9Z1(3XQ M*196M_R.LY>$1O"2&9)[ 08P;:5&TX:'CMU@'S_U@EC%>1UKRD5Y[Y=$R?R, M,FV3]B&FU(0'2=M8[^!2JGTB<<>R'*?_3IX[3\3M8B]X6 U;(6DIPT/%9J\/ MF#(&B2 ?)]85KO*&AO55,JW;AHP>+K[70N/CBRRSNZ1WCXS"#PB8$E<]#9E3 MO:V7!]'C@"F]UPL9*G2>KL;+#!.9??ANE#F;V74[]42N"H+H7=V-,4VK] M^1M/KE3INJQZVB('J_RYE.0J5%;;%C+!8L3:(D M3^CZ5W'RR1-L:Y5-Y H(V*"BP50$@0)H2^?@($1*Z1B".TXDA$1T1/$2H$PL MQ&\?'JRS?9?8%13]AA4QKR+W?1 MHS!%@!<2[#+70[_-I#[\-S5!(-!AS#@IJ:1(:7V\D'"8LM;]BX"UMT7 NF<1 ML YQ$; >N@A8>UL$J-V6*4+$N'2[2I,U!I(3=JI=0]%A6>?#(@T*%=@?.&;4 M(>@0XSJC99'B3*;GYYMB_U?B@Z65@,Y93LLNFW522YLH"$:ZG!EI+8JH9A&"4[K](BV*^+](GZ4GKY ,9O)$U_H>R5+@C.&"5Q>2W%=J>H6^_VB9D>V^V'9@!Q$#@- M<0@\.B.#QD\R"JFPZDJ8%Y*^L71+<\R+=\FY;60"=&[) 6RVB=%$ 9%B=P80 M4HM1J?;S@G:9/:)>9)6_.P0V$)([?EV[T[3VUK95&Q SG0:A=[BKG!^'M7$9 MY>D5RYS(WXM(7L@7G./*&]A>2.[ZI':'A.)EED6XI1:I8VQ LQHSABXD8"!S M!BTIB>3UEAN6HR5#7S."\D>"+JN?H6MF@B_K\?5+(U$D7X@H5^4TQMR&4)?8 M^:^.@(:-WQXQE$& U&L/_AV2.@*I$,?4W J&>?,\KC QS\D&?-NA/\0504/- M*X[Z]$'0--"DSE01UCZY+@*1C/29S:B9W!Y>XK5$CE?&%H/:PKBA"((1T!:T M+&[^5H"?W'G;59I$5RG#\%66EL9QQCS3GI8L[R (B #3%90BKQ"B0NFE_S]C M^L2WSWFTO^,L(D0^9975HU7?];>!T6Z9>5.3VC0-"@V(L[?X!0@\5($:=7QH MS%@^+^;)A\9E-C<6/2T>L3B M]L\DS.H, 9?!>\,@'5 :C1K2G\[/LD 60Q)_W]^2!P9+L\L]B1T\=9Q@#8EV? MO0UNCGXRUQL8!(1O=0N=ZF6H60%:R6?$JBK0[[(25-1B^_WRYJ9K\4EL5IO$ M7RN<$;'EOU!+ P04 " NETU5@JM8B%H' #;5P %0 &=T=FDM,C R M,C$P,3)?<')E+GAM;,V4<'=M M7VX46TE49"DCR23Y[RO9<2X_+'EY\<(#!&SLNRU))^_7Z8\>J9*,RDN M6MVCXU9$12P3)J87K2^C]N6H/QRV(FV(2 B7@EZTA&R]__/GGR+[<_Y+NQT- M&.7)6?1!QNVAF,AWT2U)Z5GTD0JJB)'J7?25\,P=D0/&J8KZ,IUS:JC]HFCX M+'ISU'U+HG8;4.]7*A*IOCP,-_7.C)GKLTYGL5@<"?E,%E(]Z:-8IK *1X:8 M3&]J.UX>KW^*XN>3?EJ8'ELNQXF4;)YW2G4W-]EL6L-_R M1+,SG;MW(V-B\K#7-A-Y+=Q_[=*L[0ZUN[WV2?=HJ9-6"3\GJ"2G#W02N;\V M>IM6_Y,+LII1PLW,Q:SCON_TI>V3UMF\Y$S1R45K:IZ9;:#7ZQYW>Z[Z7W>, MS&IN^Z9FKFNUHLY.TW-%-14F5WMC#^P4H4MC>Q1-RHI<^R]PSC#C[-==IANU M7?_*4MN<_5A8KGTIO>$RWG& NSC(/;5EG\YI:QH?3>5S)Z&LXPBX#SF*'(/] MYWO>T.58&T5B4];$R9CRO/[OUF;/I-. 5R6)1UMCM5.[%OL^;,;P(]43+UT5F3D!Y'MT'9)IJA>6G;3YP/ M TZFU3CW3( \NQA *]5@$?U =:S8W'&I ;MC">3;0^5;H:UAS.6Y\T"GS/GK M7'$77>H.AL<%3Q$@^!/,D2*H%BD"ET)DA#_0N50UX'J-AT"_X#M4@1N*>*R<1>TA6 M_8$QD/HI)G6/0E3>UR*!TMZ8@O,??-A[\I!0#YB."2\\&MAC.HR[PAR*'"7G MK)6)BOT?2A08^I8Q%#E*&EHCL6'@_4RI'6>"HXK?&HH<)0&M$]DP\VMAF%FY M)_^W63K^\>!TE_6A%90Q2M+I$X7"MGS2((R;T CQW;>$,D;)-4/B4#CWK1Y% M^% D=/F)KD*@#TRAI%%RS* \%-3WBJ5$K48LKA\T#FVAL%$RR[! %-J/9#E, MK"HV8<648#UT;Q$H>Y2T$B07)01#$4LUEUN/B_LRL^?CJB^3X)!>4Q :#I1\ M\P7248)RF206EU[_N6&"=D.AJ#0'SQ'A!2 @\Y5@[[T,>P^.'24/K97Y2K"? MO S["1P[2BY:*Q,3>]]^O%./:.W6OY#,K5D;5 M43\H 46/F**&Q:)V^.(B#^GMI264-V*Z6BT.D_.]U(;P?]F\[DZRVA[*'#%Q M#0EM^@%C$7?WT,*WE&C/!,H7)5>ME-,T4A=A18F_^^Y:0(&B)*!58AKF>2/= MW,=,BN#SV$,K*%>43-(GJNF!UZTEUMY3?^MK\ HVE&%U7T;#&+\I9JP'?9FF MF5@_H_',BGE,H7A1TK^@O(91CR1G,3-,3#_;.T3%"*_F7&4'A8R2[/F%-4SX M7E$7:6ION_-U7&ZS@;J;3'PC;\@>2APEUZL7BDM^J'5&U4OY5Y2"1@$E[8.* M;GJ]>V%9RK#<^9[AE#:B$MA*Z6A0!ZEA/.K3#-! M=7!LV3.$0D9<\UHI#07R=4K5U YJ'Y5*Q'KM1AR[A13%E5PD1'FHA^RAW%$W5OJ%-DS^SLRH MVKY_RIT9VKPMM.BAOA0T"BCI*E0TSK5U:R=_\-*Z8P?EC9B85@G#V3.5C3F+ M!UR2X'WYCAF4+V(66B$+!>\5$4\JFYMX=:]D3*F;/M&;LPV0$ $K@(8$,3]] M$0JZ"](^-7C2Y M6CW0"55NF<(C79HKV]!3^*8(4!P:']0W"H$Q5(3IO'.@Z\8><&^I+;YQO]R; M6.V1_P%02P$"% ,4 " NETU5\JY_#+D3 !?B@ %0 M@ $ 96$Q-C'-D4$L! A0#% @ +I=-51H$"V;]"@ @(8 !4 ( ! M>E$ &=T=FDM,C R,C$P,3)?;&%B+GAM;%!+ 0(4 Q0 ( "Z7356"JUB( M6@< -M7 5 " :I< !G='9I+3(P,C(Q,#$R7W!R92YX 8;6Q02P4& 8 !@"2 0 -V0 end